Potential of p38-MAPK inhibitors in the treatment of ischaemic heart disease
- 1 November 2007
- journal article
- review article
- Published by Elsevier in Pharmacology & Therapeutics
- Vol. 116 (2) , 192-206
Abstract
No abstract availableKeywords
This publication has 137 references indexed in Scilit:
- FGF1/p38 MAP kinase inhibitor therapy induces cardiomyocyte mitosis, reduces scarring, and rescues function after myocardial infarctionProceedings of the National Academy of Sciences, 2006
- p38 Mitogen Activated Protein Kinase Mediates Both Death Signaling and Functional Depression in the HeartThe Annals of Thoracic Surgery, 2005
- p38γ regulates the localisation of SAP97 in the cytoskeleton by modulating its interaction with GKAPThe EMBO Journal, 2005
- Targeted Inhibition of p38 Mitogen-activated Protein Kinase Antagonizes Cardiac Injury and Cell Death Following Ischemia-Reperfusion in VivoJournal of Biological Chemistry, 2004
- Disruption of a single copy of the p38α MAP kinase gene leads to cardioprotection against ischemia–reperfusionBiochemical and Biophysical Research Communications, 2003
- p38-dependent marking of inflammatory genes for increased NF-κB recruitmentNature Immunology, 2001
- Role of G Proteins and Modulation of p38 MAPK Activation in the Protection by Nitric Oxide against Ischemia–Reoxygenation InjuryBiochemical and Biophysical Research Communications, 2001
- Activation of p38 MAPK Induced by a Multi-cycle Ischaemic Preconditioning Protocol is Associated with Attenuated p38 MAPK Activity During Sustained Ischaemia and ReperfusionJournal of Molecular and Cellular Cardiology, 2001
- Activation of c-Jun N-Terminal Kinases and p38-Mitogen-activated Protein Kinases in Human Heart Failure Secondary to Ischaemic Heart DiseaseJournal of Molecular and Cellular Cardiology, 1999
- Hydrogen peroxide induces tumor necrosis factor α–mediated cardiac injury by a P38 mitogen-activated protein kinase–dependent mechanismSurgery, 1998